FDA顾问支持肽类，尽管存在安全担忧 · 跟踪1个来源

本文如何被排名

Signal score

0 / 100

Composite score across the factors below. Higher = stronger signal that this story matters right now.

Newsworthiness bucket

Research

该集群涵盖了一个监管机构的咨询小组就药物获取问题进行的投票，这是一个重要的政策发展。[lever_c_demoted from significant: ic=1 ai=0.1]

Source corroboration

Single-source cluster

Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.

Topics

policy

Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.

AI-industry relevance

Low

Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.

Story freshness

48 days old

Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

完整方法见我们的编辑标准。